A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study

Journal of Infectious Diseases

Volumn 185, Issue 2, 2002, Pages 178-187

  Lundgren, Jens D ^a   Mocroft, Amanda ^b   Gatell, Jose M ^c   Ledergerber, Bruno ^d   D’Arminio Monforte, Antonella ^e   Hermans, Philippe ^f   Goebel, Frank Detlef ^g   Blaxhult, Anders ^h   Kirk, Ole ^a   Phillips, Andrew N ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF MILAN   (Italy)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISRAEL; KAPOSI SARCOMA; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESOURCE MANAGEMENT; SCORING SYSTEM; VALIDATION PROCESS; VIRUS LOAD; WASTING SYNDROME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0037080037     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338267     Document Type: Article

References (47)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. AIDS-related opportunistic illnesses after initiation of potent antiretroviral therapy
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel
6. The SPICE study: 48-Week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection
9. A randomised trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 injected patients
10. The relation of virological and immunological markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
11. + lymphocyte counts and the risk of progression to AIDS
12. HIV-1 RNA levels and the development of clinical disease
13. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection
14. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals
15. + lymphocyte count improves assessment of antiretroviral response
16. Staging system for clinical AIDS patients
17. Considerations in choice of a clinical end point for AIDS clinical trials
18. A new prognostic staging system for the acquired immunodeficiency syndrome
19. The AIDS-defining diagnosis and subsequent complications: A survival based severity index
20. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
21. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
22. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy
23. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients
24. 1993 Revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults
25. Analisis de 1.187 casos consecutivos de sida: Variaciones y tendencias en el tiempo
26. Survival of AIDS patients according to type of AIDS-defining event
27. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe
28. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
29. Use of changes in plasma levels of human immunodeficiency virus type I RNA to assess the clinical benefit of antiretrovirat therapy
30. An evaluation of HIV RNA and CD4 cell counts as surrogates for clinical outcome
31. + cell counts in HIV-infected patients
32. Changes in virological markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides
33. HIV-1 RNA, CD4 cell count and risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors
34. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count
35. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection
36. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
37. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to ADS and death
38. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
39. Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
40. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
41. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
42. Long-term survival in patients with advanced immunodeficiency
43. 6/L
44. Factors influencing survival after AIDS: Report from the Multicenter AIDS Cohort Study (MACS)
45. Association between immune activation, changes in iron metabolism and anaemia in patients with HIV infection
46. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus